bioAffinity Technologies (NASDAQ:BIAF) Rating Lowered to Sell at Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Monday, July 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, bioAffinity Technologies currently has an average rating of “Sell”.

bioAffinity Technologies Price Performance

BIAF opened at $0.60 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The stock’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.67. The firm has a market cap of $2.83 million, a price-to-earnings ratio of -0.05 and a beta of -1.04. bioAffinity Technologies has a 1 year low of $0.56 and a 1 year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.59. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.48 million.

Institutional Investors Weigh In On bioAffinity Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIAF. Geode Capital Management LLC purchased a new position in bioAffinity Technologies during the 4th quarter valued at about $36,000. Scientech Research LLC purchased a new position in shares of bioAffinity Technologies during the third quarter valued at approximately $49,000. Finally, J. Safra Sarasin Holding AG bought a new stake in shares of bioAffinity Technologies in the 1st quarter worth approximately $164,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.